| [Purpose]The subject of clinical efficacy to be compared to clinical neurological deficits integral,mRS scale,plasma fibrinogen, blood fat,blood glucose and Ischemic Stroke recurrence rate, mortality rate,The incidence of adverse reactions,such as indicators to observe changes in Erigeron Shengmai Capsule on ischemic stroke secondary prevention efficacy,and its mechanism for patients to alleviate pain,improve clinical efficacy and prevention of cerebrovascular disease has important significance.[Method]Would be consistent with the standards included in the patients with Ischemic Stroke 42 cases,in accordance with the order to the group were randomly divided into two groups (treatment group,control group) of the 21 cases,the use of randomized,controlled clinical research methods.Oral treatment group Erigeron Shengmai Capsule(from Yunnan Valley Breviscapine Biology Medicine Co.Ltd.Production: Drug lot number Z20026439),each piece costs 0.18g,each two, half an hour postprandial oral,2 times daily;the control group oral comfort agent capsule(Yunnan Valley Breviscapine Biology Medicine Co.Ltd.production),each piece costs 0.18g,each two, half an hour postprandial oral,2 times daily;two groups of Chinese and Western medicine on the basis of treatment with reference to relevant standards;these drugs were continuous treatment for 6 months.Pre-treatment of two groups of gender, age,course of disease,basic diseases,such as basic information were compared by statistical treatment no significant difference(P＞0.05),note the two groups are comparable;after treatment according to clinical efficacy, the degree of clinical neurological deficit score,mRS,plasma fibrinogen,blood lipids,as well as recurrence rate,mortality rate,incidence of adverse reactions,such as indicators for evaluation,statistical analysis,to evaluate Erigeron Shengmai Capsule on secondary prevention of ischemic stroke patients.[Results]1.Clinical nerve function damage degree integral comparison:Before the treatment group treats,the integral 13.31±5.82,after the treatment,integral 8.99±5.35;Before the control group treats,the integral 13.75±6.74,after the treatment,integral 9.51±6.22.By pairedt test,the treatment group after treatment than before treatment to improve the neurological deficit score differences were significant (P＜0.05),and inter-group difference after treatment also significantly(P＜0.05).2.Lipids,blood glucose changes:To improve the Tch,TG, HDL-C,LDL-C,FBG the treatment group before and after treatment significantly decreased(P＜0.05);control group,before and after treatment there was a significant not difference(P＞ 0.05)。3.Change of plasma fibrinogen:The treatment group before treatment 4.25±1.18,after treatment 3.47±0.58;control group pre-treatment score 4.33±1.02,after treatment score 3.62±0.52.After statistical analysis,treatment group and control group before treatment Fg comparison,no significant difference(p＞0.05);two groups after treatment Fg own comparison,there is significant difference(p＜0.05);two groups after treatment Fg comparison,no significant difference(p＞0.05).4.Relapse,died of the disease and comparison of adverse reactions:The treatment group six months of the relapse rate, mortality rate are 0,the control group were 4.76%,0,compared the two groups has no significance(p＞0.05);adverse reactions aspirin is mainly due to two cases of treatment group,1 cases of the control group,control group,compared the two groups has no significance(p＞0.05).[Conclusion]The results show that with the use of Yiqi Yangyin,Huoxue Jiannao Erigeron efficacy Shengmai capsules can improve recovery in patients with ischemic stroke clinical symptoms, to a certain extent improved the lives of patients with self-care ability and reduce the level of plasma fibrinogen and to prevent the recurrence of Stroke have a certain effect.However,because of smaller sample size,observed a shorter cycle,but also to be one step into a strict program design,expanding the sample size,to carry out large-scale,multi-center clinical trial for pharmaceutical intervention in secondary prevention of ischemic stroke based on the provision of evidence-based medicine.
|
PDF Full Text Request